Remove Biobanking Remove Containment Remove Genetics Remove Life Science
article thumbnail

Drug discovery hotspots: Focus on Qatar

Drug Discovery World

DDW Editor Reece Armstrong takes a look at Qatar’s drug discovery and life sciences market, exploring how the country is utilising innovative technologies in its approach to healthcare. The Middle East represents one of the world’s most lucrative markets for pharmaceuticals.

article thumbnail

New Research Reveals How Air Pollution May Trigger Lung Cancer

XTalks

Researchers at the Francis Crick Institute and University College London in the UK have found how air pollution can trigger the activation of cells with existing genetic mutations to form cancer. In fact, one in every 600,000 cells in the lungs of a 50-year-old already contains potentially cancerous mutations. The Double Hit.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Biorepositories as a Guiding Resource for Research & Drug Discovery

XTalks

Biobanks are used for the coordination of high-yield patient sample collection. Moreover, biobanks are no longer passive biorepositories for accrual of samples and serve a more utilitarian function in identifying and coordinating specific research cohorts for longitudinal and prospective studies. Biobanking Models.

article thumbnail

HFpEF vs. HFrEF: How To Improve Heart Failure Drug Development

XTalks

A 2015 study published in Nature Genetics found that the availability of human genetic data made investigational drugs twice as likely to pass pivotal trials and eventually be approved. Figure 1: The use of Mendelian randomization to validate genetic drug targets.